转移性肾癌免疫治疗的临床研究成果（附原文）

incosc

: e5 `! H) x% `
# h2 w2 G5 [5 C" ^* G
髓源性抑制细胞与转移性肾细胞癌患者的CIK免疫治疗功效之间的相关性. k; e: f' O% {1 m* a
《免疫治疗杂志》2014年1月, L1 U3 G5 S1 x/ V& q4 ?. l
# A" c  `! }% t

* X; j; M. [: N, C转移性肾细胞癌（MRCC）是属于对免疫疗法敏感的恶性肿瘤之一。然而，潜在的免疫抑制因子，如髓源抑制细胞（MDSCs）可能会抑制免疫疗法的功效。本研究探讨细胞因子诱导的杀伤性细胞（CIK）治疗MRCC患者的临床疗效，并探讨外周血中的MDSCs的水平是否与接受治疗的患者的预后相关。29例证实的MRCC患者分别接受过继性自体CIK细胞输注，随后接受连续5天的白介素-2用药。研究者对肿瘤反应和一年生存率进行了观察，对检测到的外周血中MDSCs的比例，以及MDSCs的与预后的相关性进行了分析。 29例可评估患者中，没有观察到完全缓解，看到；4例患者表现出部分缓解（13.8%），18例显示病情稳定（62.1%），7例呈进行性疾病（24.1%）。二十名患者（69.0%）在最后一次随访的时候还活着（14.8-41.4个月，平均随访20.2个月）。1年生存率为82.8%（24/29）。几乎所有的MRCC患者表现出外周血MDSCs升高，并在CIK细胞输注后下降。亚组分析显示，MDSCs的比例相对较低的患者展示出更长的生存期。总之，数据表明自体CIK细胞回输可诱发MRCC的消退，并且MDSCs可以作为接收CIK治疗的患者预后的一个潜在标志物。 7 X: y2 r6 Y% t. m! L
' z- ]6 {7 h( @0 U4 {9 d/ k
Association of Myeloid-derived Suppressor Cells and Efficacy of Cytokine-induced Killer Cell Immunotherapy in Metastatic Renal Cell Carcinoma Patients0 N  M4 R$ C  C8 K. ^" }* z
Z. Wang et al., Journal of Immunotherapy, 2014, 37(1): 43-50
. X# S2 |2 [% U" x9 O% ]
$ \# z, `/ w4 J) V9 g& I; C% V- \2 t" \Metastatic renal cell carcinoma (MRCC) is one of the malignancies that are sensitive to immunotherapy. However, the underlying immune inhibitory factors such as myeloid-derived suppressor cells (MDSCs) might restrain the efficacy of immunotherapy. The present study investigates the clinical efficacy of cytokine-induced killer (CIK) cell therapy in patients with MRCC and explores whether the levels of peripheral MDSCs are associated with the prognosis of patients receiving this therapy. Twenty-nine patients with measurable MRCC were treated with an adoptive transfer of autologous CIK cells, followed by 5 consecutive days of interleukin-2 administration. The tumor response and 1-year survival were observed. The proportion of MDSCs in the peripheral blood was detected, and the correlation of MDSCs with prognosis was analyzed. Of 29 evaluable patients, no complete responses were seen; 4 patients exhibited a partial response (13.8%), 18 patients displayed stable disease (62.1%), and 7 patients showed progressive disease (24.1%). Twenty patients (69.0%) were alive 14.8–41.4 months at the time of the last follow-up (median follow-up=20.2 mo). The 1-year survival was 82.8% (24/29). Peripheral blood MDSCs were elevated in almost all MRCC patients and decreased after CIK-cell infusion. Subgroup analysis indicated that patients with a relatively low proportion of MDSCs exhibited prolonged survival. In conclusion, our data suggest that transfusion of autologous CIK cells can induce regression of MRCC, and MDSCs can serve as a potential marker for the prognosis of patients receiving a CIK-based therapy.
* u: V5 w% d7 u$ Y; V' s4 |) a8 N* F0 X* G
2楼原文 感谢aulenuyah 提供

aulenuyah

原文：' R/ S& w5 W# A4 u9 x( d
  B% g+ D4 g: a2 h) M) S